Formulary updates

Formulary additions (ratified at June TAMSG)

• Amivantamab solution for (subcutaneous) injection 1600mg, 2240mg (Restricted: Hospital use only) indication as per SMC advice 2834.
• Amivantamab concentrate for solution for infusion 350mg/7ml (Restricted: Hospital use only) additional indication added for SMC advice 2834.
• Durvalumab concentrate for solution for infusion 50mg/ml (Restricted: Hospital use only) (additional indication: SMC2818).
• Enfortumab vedotin powder for concentrate for solution for infusion 20mg, 80mg (Restricted: Hospital use only) indication as per SMC advice 2842.
• Impilimab concentrate for solution for infusion 5mg/mL (Restricted: Hospital use only) (additional indication: NCMAG 216).
• Lazertinib tablets 80mg, 240mg (Restricted: Hospital use only) indication as per SMC advice 2834.
• Nivolumab concentrate for solution for infusion 10mg/mL (40mg/4mL, 100mg/10mL, 120mg/12mL, 240mg/24mL) (Restricted: Hospital use only) (additional indication: NCMAG216).
• Omega-3-acid ethyl esters: Capsules 1,000 mg (docosahexaenoic acid 380mg, eicosapentaenoic acid 460mg) (Restricted: Specialist recommendation only).
• Talquetamab solution for injection 2mg/ml, 40mg/ml (Restricted: Hospital use only) indication as per SMC advice 2863.

Other formulary additions

These will be ratified at next TAMSG

• Recombinant human insulin analogues (Formulary: Endocrine) | Right Decisions
  • Insulin Lispro injection 100 units/ml, 3mL pre-filled pen added: Lyumjev Junior Kwikpen^®.
• Non-sedating antihistamines (Formulary: Respiratory) | Right Decisions
  • Added new indication: fexofenadine hydrochloride tablets 180mg for symptomatic relief of chronic idiopathic urticaria.

Formulary deletions 

These will be ratified at next TAMSG

• F408: Disposal of medicinal products: removed as not therapeutic guidance
• F349: Long-acting antimuscarinic bronchodilators (LAMA) in COPD
• Inhaled corticosteroids (ICS) (Formulary: Respiratory) | Right Decisions
  • Beclometasone, removed: dipropionate aerosol inhalation (Clenil Modulite^®) 250 micrograms/metered inhalation (discontinued).

Major formulary amendments

See the 'What's new' section of each monograph.
These will be marked as ratified or ratified at next TAMSG

• Clostridioides Difficile (Antimicrobial) | Right Decisions
  • Complete Severity Assessment: added bullet point 'For administration advice in swallowing difficulties or enteral feeding tubes, see section below'.
  • Added new section 'Administration in swallowing difficulties or enteral feeding tubes'.

Minor formulary amendments

See the 'What's new' section of each monograph.
These will be ratified at the next TAMSG

• Prostate cancer: gonadorelin analogues, and gonadotrophin-releasing hormone antagonists
  • Leuprorelin amendment: removed that it is used first line: 
• Inhalational anaesthetics (Formulary: Anaesthesia) | Right Decisions
  • Methoxyflurane amendment: Product licence for Penthrox has changed from 18 years and older to 6 years and older. Link to guideline added. 
• Angiotensin-converting enzyme (ACE) inhibitors (Formulary: Cardiovascular) | Right Decisions
  • added MHRA advice: ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (June 2026) (www.gov.uk).
• Second generation (Atypical) antipsychotics (Formulary: CNS) | Right Decisions
  • Risperidone - amended wording: '250 microgram tablets are NOT recommended to be prescribed as they are not cost effective' to '250 microgram tablets are NOT cost effective, they are NOT recommended to be prescribed, except for those patients on a 250 microgram dose to avoid splitting tablets’.
• Alpha-adrenoceptor blockers (Formulary: Cardiovascular) | Right Decisions
  • Doxazosin - amended wording: '8mg tablets are NOT recommended to be prescribed as they are not cost effective' to ‘8mg tablets are NOT cost effective, they are NOT recommended to be prescribed except for patients prescribed 16mg dose’.
• Vaccines and antisera (Formulary: Immunology & Vaccines) | Right Decisions
  • Meningococcal B - Bexsero, added: 'Time-limited Meningococcal Group B (MenB) vaccination programme see CMO letter: CMO Letterhead.dot.'
• Devices for diabetes (Formulary: Endocrine) | Right Decisions
  • Updated the Insulin / pen compatibility charts to the latest versions.
• Vitamin B group (Formulary) | Right Decisions
  • Updated guidelines section for thiamine solution for injection and parenteral vitamins b and c high potency injection.
  • Added '(250mg/5mL)' to thiamine solution for injection.
• Skin cleansers and antiseptics (Formulary: Dermatology) | Right Decisions
  • Added: link to NHS Highland patient information leaflet 'How to use Potassium permanganate'.
• GP Out of Hours Formulary: Highland HSCP (Formularies) | Right Decisions
  • Infection section:
    • Amoxicillin: amended Dental abscess from '5 days' to '3 days then review, may need 5 days'.
    • Benzylpenicillin: amended 'saline'  to 'sodium chloride 0.9%'.
    • Phenoxymethylpenicillin: amended dental abscess '5 days' to '3 days then review, may need 5 days'.
    • Doxycycline: amended 'Cellulitis 5 days then review (may need 7 days)' to 'Skin and soft tissue infection 5 days'.
    • Doxycycline: amended Hospital/Healthcare acquired pneumonia from 'up to 8 days' to '5 days'.
    • Co-trimoxazole: amended Hospital/Healthcare acquired pneumonia from 'up to 8 days' to '5 days'.
  • Anaesthesia section:
    • Added: Penthrox (methoxyflurane) inhalational vapour, liquid 99·9% 3mL.
• Domperidone and metoclopramide (Formulary: CNS) | Right Decisions
  • Domperidone, added: MHRA advice: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension (July 2026) (www.gov.uk).
• Drugs affecting the immune response (Formulary: Dermatology) | Right Decisions
  • Methotrexate 2.5mg tablet: amended from 'specialist initiation only' to 'specialist recommendation only'.
• Immunosuppressants (Formulary: GI) | Right Decisions
  • Methotrexate tablets 2.5mg: amended '(s)' to '(Restricted: Specialist recommendation only)'.
  • Methotrexate injection pre-filled syringe 7·5mg/0·15mL, 10mg/0·2mL, 12·5mg/0·25mL, 15mg/0·3mL, 17·5mg/0·35mL, 20mg/0·4mL, 22·5mg/0·45mL, 25mg/0·5mL: amended '(s)' to '(Restricted: Specialist initiation only)' and added 'To be administered via subcutaneous injection'.
• Drugs affecting the immune response (Formulary) | Right Decisions
  • Methotrexate tablets 2.5mg: amended '(s) to '(Restricted: Specialist recommendation only)'.
  • Methotrexate injection pre-filled pen 7·5mg/0·15mL, 10mg/0·2mL, 12·5mg/0·25mL, 15mg/0·3mL, 17·5mg/0·35mL, 20mg/0·4mL, 22·5mg/0·45mL, 25mg/0·5mL, 27·5mg/0·55mL, 30mg/0·6mL: amended '(s)' to '(Restricted: Specialist initiation only)' and added 'To be administered via subcutaneous injection'.

Formulary sections reviewed with no changes

These will be ratified at the next TAMSG

• Items will be added as they are published
  

Formulary monographs

*NEW* Formulary submissions (ratified at April TAMSG)

• Acalabrutinib tablets 100mg (Restricted: Hospital use only) (additional indication: SMC2893)
• Elafibrinor tablets 80mg (Restricted: Specialist initiation only) 
• Estradiol with norethisterone patches (Estradot Conti®) estradiol 30 micrograms / norethisterone 95 micrograms, estradiol 40 micrograms / norethisterone 130 micrograms.
• Lidocaine plaster 700mg
• Osimertinib tablets 40mg, 80mg (Restricted: Hospital use only) (additional indication: SMC2815)
• Pembrolizumab concentrate for solution for infusion 25mg/mL (Restricted: Hospital use only) (additional indication: SMC2829)
• Sodium zirconium cyclosilicate powder for oral suspension 5g, 10g (additional indication: SMC2288)
• Vorasidenib tablets 10mg, 40mg (Restricted: Hospital use only)

Minor additions

• Added: Arize Similac Cows milk protein free infant formula 400g: Alternative milk formulary (Formularies) | Right Decisions
• Added: Stoboclo^® is the recommended cost-effective denosumab brand (previously ratified): Other drugs for osteoporosis (Formulary: Endocrine) | Right Decisions
• Added: ondansetron orodispersible tablets 4mg, 8mg 5HT3-receptor antagonists (Formulary: CNS) | Right Decisions
• Added: Pembrolizumab solution for injection 395mg/2.4mL, 790mg/4.8mL SACT Immunotherapies (Formulary: Malignant disease) | Right Decisions
• Added: Freestyle Libre 3 Plus Devices for diabetes (Formulary: Endocrine) | Right Decisions
• Added: Candesartan tablets 2mg, 4mg, 8mg, 16mg, 32mg Migraine prophylaxis: General prescribing | Right Decisions
• Added: Gliclazide tablets 40mg Sulfonylureas (Formulary: Endocrine) | Right Decisions
• Added: Donepezil tablets 10mg Dementia (Formulary: CNS) | Right Decisions

Deletions

• Removed: eye drops (antazoline 0·5%, xylometazoline 0·05%) (Otrivine Antistin®) (discontinued): Other anti-inflammatory eye preparations (Formulary) | Right Decisions
• Removed: insulin degludec solution for injection 100 units/mL3mL pre-filled pen (Tresiba FlexTouch®) (discontinued): Long-acting insulins (Formulary: Endocrine) | Right Decisions
• Removed: Similac Alimentum (discontinued): Alternative milk formulary (Formularies) | Right Decisions
• Removed: ondansetron oral lyophilisates 4mg, 8mg (discontinued) 5HT3-receptor antagonists (Formulary: CNS) | Right Decisions
• Removed Freestyle Libre 3 Devices for diabetes (Formulary: Endocrine) | Right Decisions

Formulary sections

Additions

• Disposal of medicinal products (Guidelines: Medicine Management) | Right Decisions (Awaiting ratification)
• Community Pharmacy (Formularies)
• Headache and migraine (Formulary: CNS) | Right Decisions

Deletions

• Pharmacy First (Formularies): Replaced with Community Pharmacy (Formularies)

Amendments

To view the changes, see the 'What's new' section.
These will be ratified at the next TAMSG.

• Vaccines and antisera (Formulary: Immunology & Vaccines) | Right Decisions
  • COVID-19 vaccine information added. (Information incorporated from COVID124 and COVID Vaccine section on TAM)
• Devices for diabetes (Formulary: Endocrine) | Right Decisions
  • Freestyle Libre 3 Plus.
    • Amended: 'Can be used for up to 14 days' to 15 days.
    • Added: 'Has improved Bluetooth to enable linking to insulin pump Apps'.
    • Removed: 'When a new ‘reader’ is ordered an envelope will be sent to return the old reader/meter to Abbot for recycling.  For further information, see: website'.
  • Changed BD Viva needles to Viva needles.
• Midwife exemption formulary (Formularies) | Right Decisions
  • Amended: statement added to IV fluids: NOTE: Maintelyte and Plasmalyte are NOT included in the Midwives' Exemption list and therefore MUST be prescribed before being administered.
• Alternative milk formulary (Formularies) | Right Decisions
  
  • Amendment: SMC Althera changed from 450g to 400g
  • Amendment: Neocate LCP changed from 400g to 420g
  • Amendment: place in therapy added for each item. 
  • Amendment:
    • Changed from:

      Prescribe a ‘one off’ script. Do NOT arrange repeat script at this stage.

      • All prescriptions for alternative formulas should be prescribed as an acute prescription.
      • Approximately 10 tins will be required per 4 weeks. 
      • Prescription should continue until 12 months of age minimum and ongoing, if deemed necessary under dietetic review.

      A repeat script, if required, is ONLY on dietetic request after 12 months of age.

    • Changed to: 
      • Prescribe a one-off prescription while awaiting diagnosis
      • If Dietitian has advised: prescribe as a repeat prescription with a stop date of the child’s first birthday.
      • Approximately 10 tins will be required per 4 weeks.
      • Further prescriptions, after 12 months of age, are at dietetic request ONLY.
  • Amendment: Changed from: 'Initiate milk reintroduction advice: Argyll and Bute: between 9 to 12 months or following 6 months exclusion, North Highland: between 8 to 12 months or following 6 months exclusion'. Changed to: 'Initiate milk reintroduction advice at around 12-month review'.
• Prostate cancer: gonadorelin analogues, and gonadotrophin-releasing hormone antagonists (Formulary: Malignant disease) | Right Decisions
  • For triptorelin added: Note: These products are NOT interchangeable due to their differing lengths of action.
• Hypothalamic hormones (Formulary: Endocrine) | Right Decisions
  • Added: indication for specialist use only: dynamic function testing for suspected delayed or precocious puberty.
• Gonadorelin analogues (Formulary: Endocrine) | Right Decisions
  • Gonadotrophin-dependent precocious puberty indication listed under the monograph for triptorelin 22.5mg preparation and not added to 11.25mg preparation. 
• Devices for respiratory conditions (Formulary: Respiratory) | Right Decisions
  • List of compatible devices replaced with link to RightBreathe. 
  • Spacer recommended for all patients on pMDIs rather than just high-dose steroids or sub-optimal technique. 
  • Comment re superiority of large versus small volume spacer changed from is to may be. 
  • Cleaning and storage instructions removed with reference that such information is provided with the device.
• Parenteral progestogen-only contraceptives (Formulary: Sexual Health) | Right Decisions
  • Etonogestrel (Nexplanon^®) is now licensed for 5 years (previously 3 years). See: CoSRH CEU statement_Nexplanon.pdf
  • Merged the Sayana Press (Guidelines) into the medroxyprogesterone acetate suspension for injection monograph.
• SACT Immunotherapies (Formulary: Malignant disease) | Right Decisions 
  • Amendment: Atezolizumab solution for injection 1,875mg/15mL (125mg/mL) indications added for the following SMC advice 2492, 2379, 1336/18, 2279, 2267, 2349.
  • Amendment: Nivolumab concentrate for solution for infusion 240mg/12mL changed to 240mg/24mL (error).
• Calcium and vitamin D (Formulary: Endocrine) | Right Decisions
  • Colecalciferol with calcium carbonate changed from: 'Caplets (Adcal-D3®) (calcium 300mg (7·5mmol), vitamin D 5 micrograms (200 units)/caplet)' to 'Caplets (Adcal-D3®) (calcium 750mg (18.75mmol), vitamin D 5 micrograms (200 units)/caplet)'.
• Prostate cancer: gonadorelin analogues, and gonadotrophin-releasing hormone antagonists (Formulary: Malignant disease) | Right Decisions
  • Leuporelin:
    • Added: Note: These products are NOT interchangeable due to their differing lengths of action.
    • Amendment: separated out the monthly and 3-monthly formulations.
    • Amendment: changed subcutaneous to subcutaneous or intramuscular injection (Prostap SR DCS^®) 3·75mg.
  • Triptorelin:
    • Amendments: separated out the 3-monthly and 6-monthly formulations.
    • Added: brand name (Decapeptyl SR®).
  • Degarelix:
    • Added: indication as per SMC 560/09.
• Alpha-adrenoceptor blockers (Formulary: Cardiovascular) | Right Decisions
  • Doxazosin - added: 8mg tablets are NOT recommended to be prescribed as they are not cost effective.
• Urinary retention: Alpha-blockers (Formulary: Genito-urinary) | Right Decisions
  • Doxazosin - added: 8mg tablets are NOT recommended to be prescribed as they are not cost effective.
• Second generation (Atypical) antipsychotics (Formulary: CNS) | Right Decisions
  • Risperidone - added: 250 microgram tablets are not recommended to be prescribed as they are not cost effective.
• Other antidepressants (Formulary: CNS) | Right Decisions
  • Venlafaxine - added: Note: Other strengths of venlafaxine MR tablets are not recommended to be prescribed as they are no cost effective.
• Hormonal preparations for vaginal atrophy (Formulary: Sexual Health) | Right Decisions
  • Estradiol - amended: 'vaginal tablet' to 'pessary'.
• Drugs affecting the immune response (Formulary: Dermatology) | Right Decisions
  • Methotrexate 2.5mg tablet: amended from 'hospital use only' to 'specialist initiation only'.

Additions

*NEW* Formulary submissions (ratified at February TAMSG)

• Chlormethine gel 160 micrograms/g (Ledaga®) (Restricted: Hospital use only)
• Oxybuprocaine hydrochloride eye drops 0.5mL unit dose 0.4% 
• Somapacitan solution for injection in pre-filled pen (Restricted: Specialist recommendation only)
• Triamcinolone acetonide intravitreal injection (Intracinol®) 40mg/mL (4% w/v) (Restricted: Specialist use only)
• Zolbetuximab powder for concentrate for solution for infusion 100mg (20mg/ml)

Minor additions 

• SACT Immunotherapies (Formulary: Malignant disease) | Right Decisions
  • Nivolumab concentrate for solution for infusion 120mg/12mL
  • Nivolumab solution for injection 600mg/5mL

Deletions

• none to note

Amendments

To view the changes, see the 'What's new' section.
These will be ratified at the next TAMSG.

• GLP-1 RA & dual GIP/GLP-1 RA (Formulary: Endocrine) | Right Decisions
• Vitamin C (Formulary) | Right Decisions
• Anticoagulant reversal agents (Formulary: Cardiovascular) | Right Decisions
• Prophylaxis of migraine (Formulary) | Right Decisions
• Status epilepticus (Formulary: CNS) | Right Decisions
• Valproate (Formulary: CNS) | Right Decisions
• Phenytoin, carbamazepine, sodium valproate and lamotrigine (Formulary: CNS) | Right Decisions
• GP Out of Hours Formulary: Highland HSCP (Formularies) | Right Decisions
• Oral potassium (Formulary) | Right Decisions
• Dopaminergic drugs (Formulary: Endocrine) | Right Decisions
• Obstetrics (Formulary: O&G) | Right Decisions
• Midwife exemption formulary (Formularies) | Right Decisions
• SACT Immunotherapies (Formulary: Malignant disease) | Right Decisions
• Inotropic sympathomimetics (Formulary: Cardiovascular) | Right Decisions

Additions

*NEW* Formulary submissions (ratified at December TAMSG)

• Amivantamab concentrate for solution for infusion 350mg/7ml 
• Durvalumab solution for infusion 50mg/ml (additional indication)
• Isatuximab concentrate for solution for infusion 20mg/ml (additional indication)
• Ribociclib tablets 200mg (additional indication)
• Tremlimumab concentrate for solution for infusion added (to be used in combination with durvalumab)
• Sunscreen lotion (Anthelios®) SPF 50+ 250mL

Minor additions 

• Topical retinoids and related preparations for acne (Formulary: Dermatology) | Right Decisions
  • Adapalene with benzoyl peroxide gel (Epiduo®) (adapalene 0·3%, benzoyl peroxide 2·5%)
• Leukotriene receptor antagonists (Formulary: Respiratory) | Right Decisions
  • Montelukast 5mg chewable tablets
• Antiplatelets (Formulary: Cardiovascular) | Right Decisions
  • Dipyridamole modified release capsules 200mg
  • Ticagrelor 90mg tablets and orodispersible tablets (off-label)

Deletions

• Benzoyl peroxide (Formulary: Dermatology) | Right Decisions
  • Benzoyl peroxide aqueous gel 10% (discontinued)
• Wound management guidelines and formulary (Formularies) | Right Decisions
  • Flamazine (silver sulfadiazine) 1% cream 50g tube (discontinued)
• Selective serotonin re-uptake inhibitors (SSRIs) (Formulary: CNS) | Right Decisions
  • Paroxetine oral suspension 10mg/5mL (unlicensed and other licensed SSRI liquids are available)
• Prostate cancer: gonadorelin analogues, and gonadotrophin-releasing hormone antagonists (Formulary: Malignant disease) | Right Decisions
  • Relugolix tablets 120mg (Formulary review)

Amendments

To view the changes, see the 'What's new' section.

• Alcohol dependence (Formulary: CNS) | Right Decisions (section review - already ratified)
• Respiratory syncytial virus (Formulary) | Right Decisions
• Devices for diabetes (Formularies) | Right Decisions
• Bipolar affective disorder (Formulary: CNS) | Right Decisions
• Tetracyclines (Formulary: Infections) | Right Decisions
• Other antibacterials (Formulary: Infections) | Right Decisions
• Oral preparations for acne (Formulary: Dermatology) | Right Decisions
• Benzoyl peroxide (Formulary: Dermatology) | Right Decisions
• Topical retinoids and related preparations for acne (Formulary: Dermatology) | Right Decisions
• Topical antibacterials for acne (Formulary: Dermatology) | Right Decisions
• Bisphosphonates used in malignant disease (Formulary: Endocrine) | Right Decisions
• Wound management guidelines and formulary (Formularies) | Right Decisions
• Topical NSAIDs and counter-irritants (Formulary) | Right Decisions
• Neuropathic pain (Formulary: CNS) | Right Decisions
• Midwife exemption formulary (Formularies) | Right Decisions
• Other vaginal infections (Formulary: Sexual Health) | Right Decisions
• Devices for respiratory conditions (Formulary: Respiratory) | Right Decisions
• Stimulant laxatives (Formulary: GI) | Right Decisions
• GP Out of Hours Formulary: Highland HSCP (Formularies) | Right Decisions
• Vaccines and antisera (Formulary: Immunology & Vaccines) | Right Decisions
• Sunscreen preparations (Formulary: Dermatology) | Right Decisions
• Oral potassium (Formulary) | Right Decisions

Additions

*NEW* Formulary submissions (ratified at October TAMSG)

• Thiamine solution for injection 50mg/mL (Licensed and Unlicensed preparations)
• Buprenorphine oral lyophilisate tablet (Espranor®) 2mg, 8mg (Restricted: Specialist recommendation only (May ONLY be initiated in Primary Care under the recommendation of the Specialist))
• Naloxone nasal spray unit dose 26mg/0.1mL
• Naloxone nasal spray unit dose (Nyxoid®) 1.8mg/0.1mL 
• Nirsevimab solution for injection, pre-filled syringe (Beyfortus®) 100mg/mL, 50mg/0.5mL (Restricted: Hospital use only)
• Belantamab mafodotin powder for concentrate for solution for infusion
• Bevacizumab solution for infusion 25mg/mL (additional indications)
• Blinatumomab powder for concentrate and solution for solution for infusion 38.5 micrograms
• Durvalumab solution for infusion 50mg/ml (additional indication)
• Fruquintinib capsules 1mg, 5mg
• Nirsevimab solution for injection prefilled syringe 100mg/mL, 50mg/0.5mL
• Rucaparib tablets 200mg, 250mg, 300mg (additional indication)

Additions

• GLP-1 RA & dual GIP/GLP-1 RA (Formulary: Endocrine) | Right Decisions
  • Added: New formulation Rybelsus tablets (1.5mg. 4mg and 9mg strengths) with supporting information. 
• Other antiemetics (Formulary: CNS) | Right Decisions
  • Haloperidol: added oral liquid 5mg/5mL
• Chorea and tics (Formulary: CNS) | Right Decisions
  • Haloperidol: added oral liquid 5mg/5mL
• First generation (Typical) antipsychotics (Formulary: CNS) | Right Decisions
  • Haloperidol: added oral liquid 5mg/5mL
• Dementia (Formulary: CNS) | Right Decisions
  • Rivastigmine: additional strength for the transdermal patch 13.3mg/24 hours 
• Bisphosphonates used in osteoporosis (Formulary) | Right Decisions
  • Ibandronic acid infusion 6mg/6mL (Restricted: Hospital use only)

Deletions:

• Other antiemetics (Formulary: CNS) | Right Decisions
  • Haloperidol: removed oral liquid 2mg/mL and 10mg tablets
• Chorea and tics (Formulary: CNS) | Right Decisions
  • Haloperidol: removed oral liquid 10mg/5mL and 10mg tablets
• First generation (Typical) antipsychotics (Formulary: CNS) | Right Decisions
  • Haloperidol: removed oral liquid 2mg/mL and 10mg tablets

Minor amendments

To view the changes, see the 'What's new' section.

• Vaccines and antisera (Formulary) | Right Decisions
• Dementia (Formulary: CNS) | Right Decisions
• Bisphosphonates used in osteoporosis (Formulary) | Right Decisions
  
  • Added: Ibandronic acid tablets 150mg
• Bisphosphonates used in malignant disease (Formulary) | Right Decisions
  • Deleted: Ibandronic acid tablets 150mg

Additions

*NEW* Formulary submissions (ratified at August TAMSG)

• Pravastatin tablets 10mg, 20mg, 40mg
• Ripretinib tablets 50mg
• Brentuximab vedotin powder for concentrate for solution for infusion 50mg (additional indication)
• Osimertinib tablets 40mg, 80mg (additional indication)
• Pembrolizumab concentrate 25mg/ml (additional indication)
• Selpercatinib capsules 40mg, 80mg (additional indication)
• Zanubrutinib hard-capsules 80mg (additional indication)
• Weak opioid analgesics (Formulary: CNS) | Right Decisions
  • codeine syrup 15mg/5mL
• Wound management guidelines and formulary (Formularies) | Right Decisions
  • 2 Layer Bandage System: UrgoKTwo Reduced compression 18 to 25 cm ankle (10cm)
  • 2 Layer Bandage System: UrgoKTwo Reduced compression 25 to 32 cm ankle (10cm)
• Local corticosteroid injections (Formulary) | Right Decisions
  • Dexamethasone injection (as sodium phosphate) 3·3mg/mL, 6·6mg/2mL

Deletions:

• Weak opioid analgesics (Formulary: CNS) | Right Decisions
  • codeine syrup 25mg/5mL (discontinued)
• Specific drugs (Formulary: Poisoning) | Right Decisions
  • Procyclidine solution for injection 10mg/2mL (discontinued)
• Antimuscarinics for extrapyramidal side-effects (Formulary: CNS) | Right Decisions
  • Procyclidine solution for injection 10mg/2mL (discontinued)
• GP Out of Hours Formulary: Highland HSCP (Formularies) | Right Decisions
  • Procyclidine solution for injection 10mg/2mL (discontinued)
• Anaphylaxis (Formulary) | Right Decisions
  • Adrenaline/epinephrine (Emerade®) 500 micrograms pre-filled pen (discontinued)
• Local corticosteroid injections (Formulary) | Right Decisions
  • Triamcinolone injection (as acetonide) (aqueous suspension) 40mg/mL (discontinued)

Minor amendments

To view the changes, see the 'What's new' section.

• Parenteral progestogen-only contraceptives (Formulary: Sexual health) | Right Decisions
• Midwife exemption formulary (Formularies) | Right Decisions
• Proton pump inhibitors (Formulary) | Right Decisions
• Devices for diabetes (Formularies) | Right Decisions
• Hypnotics (Formulary: CNS) | Right Decisions
• Aminosalicylates (Formulary) | Right Decisions
• Corticosteroid with antibacterial (Formulary) | Right Decisions
• Local corticosteroid injections (Formulary) | Right Decisions

New formulary entries

• Midwife exemption formulary (Formularies) | Right Decisions

Formulary updates

To view the changes, see the 'What's new' section.

• Statins (Formulary: Cardiovascular) | Right Decisions

Formulary updates

To view the changes, see the 'What's new' section.

• Devices for diabetes (Formularies) | Right Decisions
• Scottish Perinatal Network (SCBU Formulary) | Right Decisions
• Wound management guidelines and formulary (Formularies) | Right Decisions

To view the changes, see the 'What's new' section.

• Urokinase for blocked central venous access device (CWard Formulary) | Right Decisions
• Benzylpenicillin (SCBU Formulary) | Right Decisions
• GLP-1 RA & dual GIP/GLP-1 RA (Formulary: Endocrine) | Right Decisions

Items will be added as they are published. 

Additions: 

• Devices for diabetes (Formularies)

Deletions: 

• Diagnostic and monitoring devices for diabetes: CGM, BGM, Urinalysis
• Needles

Removed 

• Guide to Highland Formulary inhaler devices (Formulary)

New ancillary formulary:

• Symptomatic relief formulary (Formularies) | Right Decisions (scot.nhs.uk)

Ancillary formulary updates:  

To view the changes to the formulary, see the 'What's new' section of each entry.

• Wound management guidelines and formulary (Formularies) | Right Decisions (scot.nhs.uk)
• Compression hosiery formulary: Highland HSCP only (Formularies) | Right Decisions

• SMC website
• SMC Code of Practice on Declarations of Interest
• Policy for dealing with SMC advice
• NHS Highland decisions on SMC advice published from January 2016
• NHS Highland decisions on SMC advice published up to December 2015

Central Alerting System provides links to: 

• National Patient Safety Alerts
• Department of Health and Social Care
• Medicines and Healthcare products Regulatory Agency 
  • Alerts, recalls and safety information: medicines and medical devices
  • Drug Safety Update
  • Yellow Card: Report a problem with a medicine or medical device
  • Marketing authorisations and licensing guidance
  • Product information about medicines
  • Medical devices regulation and safety
  • Latest information for patients
  • MHRA guidance on coronavirus (COVID-19)
  • About MHRA
  • All MHRA services and information
• NHS England
• UKHSA

Formulary additions (ratified at X TAMSG)

• Items will be added as they are published.

Other formulary additions

These will be ratified at next TAMSG

• Items will be added as they are published.

Formulary deletions 

These will be ratified at next TAMSG 

• Items will be added as they are removed.

Major formulary amendments

See the 'What's new' section of each monograph.
These will be marked as ratified or ratified at next TAMSG

• Items will be added as they are published.

Minor formulary amendments

See the 'What's new' section of each monograph.
These will be ratified at the next TAMSG

• Items will be added as they are published.

Formulary sections reviewed with no changes

These will be ratified at the next TAMSG

• Items will be added as they are published